Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 5,359 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AIDS Clear all
Terminated Phase 1 Interventional

Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination

NCT00006153
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 3 Interventional

Alternative Stress Management Approaches in HIV Disease

NCT00029237
View directory record Official record
Conditions
HIV Infections
Interventions
Cognitive-behavioral relaxation (Positively Living), Spiritual growth group, Focused Tai Chi
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit

NCT04804072
View directory record Official record
Conditions
HIV Infections, Drug Use, Opioid Use, Opioid-use Disorder
Interventions
Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD), HIV testing, HIV treatment for participants living with HIV not already in care, PrEP for participants without HIV, Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV), Testing and referral for treatment for hepatitis C virus (HCV), Sexually transmitted infection (STI) testing and treatment, Primary care, Harm reduction services, Peer navigation, COVID-19 testing and referral for further evaluation, care and/or treatment
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Not yet recruiting No phase listed Observational

Comparison of the Body Roundness Index and A Body Shape Index With Body Fat and Visceral Fat in People Living With HIV.

NCT07203261
View directory record Official record
Conditions
HIV/AIDS
Interventions
Not listed
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

NCT01231542
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572, Rifampin, Rifabutin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Not applicable Interventional

Intervening With Haitian Immigrants in the U.S. to Improve HIV Outcomes

NCT05947266
View directory record Official record
Conditions
HIV Infection Primary
Interventions
an adaptation of the iENGAGE
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

NCT04585737
View directory record Official record
Conditions
HIV I Infection
Interventions
Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
Drug
Lead sponsor
Charlotte-Paige Rolle, MD
Other
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 20, 2026, 10:04 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

NCT06332339
View directory record Official record
Conditions
HIV
Interventions
16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV

NCT05314088
View directory record Official record
Conditions
Resilience, HIV-1-infection, Stress, Psychological
Interventions
RISE+, Stress Reduction Control
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed No phase listed Observational

Neurobehavioral Model of HIV in Injection Drug Users

NCT00198861
View directory record Official record
Conditions
Drug Abuse, HIV Infections
Interventions
Injection and Non-Injection Drug Users
Other
Lead sponsor
The City College of New York
Other
Eligibility
15 Years to 50 Years
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

NCT02935686
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 20, 2026, 10:04 PM EDT
Terminated Phase 1 Interventional

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

NCT06430905
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2, Placebo
Biological · Other
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Orlando, Florida • Decatur, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 20, 2026, 10:04 PM EDT
Not listed Phase 2 Interventional

Reducing Proviral HIV DNA With Interferon-a

NCT02227277
View directory record Official record
Conditions
HIV, HIV/AIDS
Interventions
Peg-IFN-α2b
Drug
Lead sponsor
The Wistar Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Multi-Component Intervention to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV

NCT04549259
View directory record Official record
Conditions
HIV
Interventions
Group-Based Social Support, HIV Stigma Reduction, Strengths-Based Case Management (SBCM), Personalized Technology Detailing
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
50 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Improving Quality of Life for Adults Living With HIV and Chronic Pain

NCT05055596
View directory record Official record
Conditions
HIV Infections, Chronic Pain
Interventions
Tai Chi, Health Coaching
Behavioral
Lead sponsor
Temple University
Other
Eligibility
45 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Alcohol & Metabolic Comorbidities in PLWHA: Evidence Driven Interventions

NCT03299205
View directory record Official record
Conditions
HIV/AIDS, Dysglycemia, Alcohol Use Disorder
Interventions
Exercise
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Relationship of Exercise, Sleep, and Inflammation Markers in People Living With HIV

NCT04946994
View directory record Official record
Conditions
Hiv, Sleep
Interventions
HIIT, CME
Behavioral
Lead sponsor
Christine Horvat Davey
Other
Eligibility
50 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

NCT01403051
View directory record Official record
Conditions
HIV-1 Infection
Interventions
EFV/FTC/TDF, Calcium Carbonate, Vitamin D3, Placebo for calcium carbonate, Placebo for vitamin D3
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

NCT00002175
View directory record Official record
Conditions
HIV Infections
Interventions
Dinitrochlorobenzene
Drug
Lead sponsor
The Honolulu Medical Group
Other
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional

An Effective Alternative to the Standard Referral System for HIV Testing in the Emergency Department During Off Hour Tours: A Randomized Trial

NCT00218881
View directory record Official record
Conditions
HIV Counseling and Testing, HIV Infections
Interventions
HIV educational video
Procedure
Lead sponsor
North Bronx Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2005 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Mobile Health Application to Improve HIV Medication Adherence

NCT02676128
View directory record Official record
Conditions
HIV, Medication Adherence, Mobile Health
Interventions
Twine Collaborative Care Application, Information-Motivation-Behavioral Skills Model of ART Adherence
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS

NCT00000975
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 10:04 PM EDT
Completed Not applicable Interventional

A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)

NCT00002028
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 16, 2007 · Synced Oct 20, 2026, 10:04 PM EDT